Cardiopulmonary risk is defined as the risk of serious respiratory and/or cardiovascular events in patients with chronic obstructive pulmonary disease (COPD). These include, but are not limited to, COPD exacerbations, myocardial infarction, stroke, heart failure decompensation, arrhythmia, and death due to any of these events.
AstraZeneca, a proud Partner in Health of the Ohio Academy of Family Physicians, is pleased to share its Cardiopulmonary Risk Infographic which illustrates the importance of managing COPD effectively to mitigate cardiopulmonary event risks.
For additional education and information watch the video COPD Pathophysiology & Management Considerations & GOLD 2025 Report and view the 2025 GOLD Report and infographic.
Looking to put these updated resources and materials to work right away in your practice? Utilize the OAFP’s EasyPI: COPD track to complete a self-guided performance improvement (PI) project focused on COPD in practice that will earn you American Board of Family Medicine (ABFM) PI and continuing medical education (CME) credit.